Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Terminated 3Recruiting 2No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 7Other hematologic neoplasm 5Classical hematology 3Lymphoid 2

Conditions

Anemia 43Anemia, Refractory, with Excess of Blasts 40Leukemia, Myeloid, Acute 38Myelodysplastic Syndromes 36Leukemia 34Neoplasms 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Multiple Myeloma 25Thrombocytopenia 23Leukemia, Lymphocytic, Chronic, B-Cell 21Primary Myelofibrosis 20Lymphoma 20Lymphoma, Non-Hodgkin 19Leukemia, Myelomonocytic, Chronic 18Venous Thromboembolism 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Hodgkin Disease 16Myeloproliferative Disorders 15Lymphoma, Mantle-Cell 14Anemia, Aplastic 14Anemia, Refractory 13Lymphoma, Follicular 12Hematologic Neoplasms 12Lymphoma, Large B-Cell, Diffuse 11Congenital Abnormalities 10Neoplasms, Plasma Cell 9Myelodysplastic-Myeloproliferative Diseases 9Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myeloid, Chronic-Phase 9Burkitt Lymphoma 9

Interventions

11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2Sertraline 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Bone Marrow Diseases × Classical hematology × Clear all
NCT02452983 2022-06-02

SS1

Baylor College of Medicine

Phase 1 Terminated
14 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Preleukemia

NCT02055781 2021-11-18

PAC326

CTI BioPharma

Phase 3 Terminated
311 enrolled 12 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT01773187 2020-09-29

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

CTI BioPharma

Phase 3 Terminated
327 enrolled 11 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡